|
Bullous pemphigoid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To begin to characterize the 230-kD bullous pemphigoid antigen (BPA) gene, we performed Southern analysis on genomic DNA with probes derived from 7 kb of cDNA that spans most of the coding region of this hemidesmosomal plaque protein.
|
1906508 |
1991 |
|
Bullous pemphigoid
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mucous membrane pemphigoids (MMPs) and bullous pemphigoid (BP) are autoimmune bullous diseases that share physiopathological features: both can result from autoantibodies directed against BP180 or BP230 antigens.
|
29881377 |
2018 |
|
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bullous pemphigoid (BP) is an autoimmune blistering disease associated with autoantibodies against BP180 and/or BP230 antigens.
|
31603994 |
2020 |
|
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bullous pemphigoid (BP) is an autoimmune bullous disease characterized by autoantibody production against BP180 and BP230.
|
29423547 |
2018 |
|
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
LHGDN |
Experimental bullous pemphigoid generated in mice with an antigenic epitope of the human hemidesmosomal protein BP230.
|
15725571 |
2005 |
|
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bullous pemphigoid (BP) is an acquired autoimmune skin disease, and its target antigens are a 230 kDa plaque protein (BP230) and a 180 kDa transmembrane protein with interrupted collagenous domains (BP180, type XVII collagen), which localize at the hemidesmosome.
|
10959044 |
2000 |
|
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Southern hybridizations suggested that the BP antigen gene (BPAG1) is present as a single copy in the human genome.
|
2045679 |
1991 |
|
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two hemidesmosomal components are the bullous pemphigoid (BP) antigens: BP230 shows homology to desmoplakin, a desmosomal component; BP180 contains extracellular collagen domains.
|
8250577 |
1993 |
|
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
As the BPAG1 gene encodes the epithelial isoform of BP antigen 1 (BPAG1-e), a major autoantigen of BP, as well as additional variants expressed in the neurones of the CNS and peripheral nervous system and in Schwann cells, we tested the hypothesis that products of the BPAG1 gene act as shared autoantigens in both BP and MS.
|
15787824 |
2005 |
|
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
While historically BP has been characterized as an IgG driven disease mediated by anti-BP180 and BP230 IgG autoantibodies, developments in recent years have further elucidated the role of eosinophils and IgE autoantibodies.
|
30042946 |
2018 |
|
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collagen XVII and dystonin-e have been identified as target antigens.BP affects mostly the elderly.
|
28286109 |
2017 |
|
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have found an association between BP, ND and specific serologic profile characterized by higher levels of anti-BP180 and anti-BP230 (t(45)=2.319, p=0.025 and t(45)= 2.486, p=0.017, respectively), as compared to BP patients without ND.
|
30062977 |
2018 |
|
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
BPAG1 is an auto-antigen in the skin disease bullous pemphigoid (BP) and anti-BPAG1 auto-antibodies are detectable in sera from BP patients and are used for BP diagnosis.
|
20479946 |
2010 |
|
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Two proteins, BP180 and BP230, have been identified as primary targets of autoantibodies in BP.
|
10379705 |
1999 |
|
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings demonstrate that antibodies against BP230 can elicit the clinical and immunopathological features of BP in neonatal mice, suggesting that anti-BP230 antibodies may possibly play a pathogenic role in this disease.
|
15725571 |
2005 |
|
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bullous pemphigoid (BP) is a common autoimmune blistering disease in which autoantibodies target the hemidesmosomal components BP180 and/or BP230 in basal keratinocytes.
|
31191560 |
2019 |
|
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bullous pemphigoid (BP) is an autoimmune bullous skin disease characterized by anti-BP180 and anti-BP230 autoantibodies (AAbs).
|
29619029 |
2018 |
|
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Instead, circulating autoantibodies directed to both collagen XVII, also named BP180, and BP230, are hallmarks of the autoimmune blistering disease bullous pemphigoid (BP).
|
31709656 |
2020 |
|
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although both its large size and poor solubility limit production of BP230, the developed yeast system provides cellular fractions enriched in BP230 recombinant proteins that constitute useful tools for the diagnosis of bullous pemphigoid.
|
12767802 |
2003 |
|
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
IgG and IgE autoantibodies against the hemidesmosomal antigens Bullous Pemphigoid (BP) 180 and BP230 are of pathogenic relevance, since autoantibody-antigen binding results in complement activation, immune cells infiltration, impaired hemidesmosomal function, and loss of dermal-epidermal adhesion.
|
30769277 |
2019 |
|
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
There are several lines of evidence indicating that the physiopathological bases of bullous pemphigoid (BP), the most common subepidermal autoimmune bullous disease, are hallmarked by the production of autoantibodies directed against the hemidesmosomal anchoring proteins BP180 and BP230.
|
31312206 |
2019 |
|
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bullous pemphigoid (BP) is the most prevalent autoimmune skin blistering disease and is characterized by the generation of autoantibodies against the hemidesmosomal proteins BP180 (type XVII collagen) and BP230.
|
31824475 |
2019 |
|
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
As the BP autoantigen primary structures are known, the question was addressed as to whether it is possible to demonstrate circulating antibodies against BP autoantigens (BPAG1 and BPAG2) by means of an ELISA system, using antigenic epitopes.
|
10867809 |
2000 |
|
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bullous pemphigoid (BP) is the most common autoimmune blistering disease and is linked to IgG recognition of 2 hemidesmosomal antigens, that is, BP230 (BP antigen 1) and BP180 (BP antigen 2, collagen XVII).
|
28101965 |
2017 |
|
Bullous pemphigoid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bullous pemphigoid (BP) is an autoimmune blistering skin disorder characterized by circulating serum IgG antibodies against two hemidesmosomal proteins: BP180 and BP230.
|
27709645 |
2017 |